Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 11, 2009, Pages 1053-1063

  Roumie, Christianne L ^a,b,c,d,e   Choma, Neesha N ^a,b,c,e   Kaltenbach, Lisa ^e   Mitchel Jr , Edward F ^e   Arbogast, Patrick G ^e   Griffin, Marie R ^a,b,d,e  

^a Veterans Administration   (United States)

^b Center for Patient Healthcare Behavior   (United States)

^c VA MEDICAL CENTER   (United States)

^d VA Tennessee Valley   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Epidemiology; Myocardial infarction; NSAIDs; Stroke

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STROKE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CORONARY DISEASE; CYCLOOXYGENASE 2 INHIBITORS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TENNESSEE;

EID: 70549111209     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1820     Document Type: Article

References (37)

1. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28: 67-81. (Pubitemid 28164809)
2. Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 2005; 35: 347-385. (Pubitemid 41581673)
3. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520- 1528 2 p following 1528. (Pubitemid 30844348)
4. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102. (Pubitemid 40365350)
5. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Jama 2006; 296: 1633-1644. (Pubitemid 44511610)
6. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
7. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. Jama 2006; 296: 1619-1632. (Pubitemid 44511609)
8. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006; 37: 1725-1730. (Pubitemid 44297720)
9. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884. (Pubitemid 44315980)
10. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. Br Med J 2006; 332: 1302-1308. (Pubitemid 44365384)
11. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54: 1378-1389.
12. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080. (Pubitemid 40365348)
13. International Classification of Diseases. Ninth Revision, Clinical Modi- fication. Washington, DC: Public Health Service, US Dept of Health and Human Services, 1988.
14. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003; 158: 915-920. (Pubitemid 37323253)
15. Rosamond WD, Chambless LE, Sorlie PD, et al. Trends in the sensitivity, positive predictive value, false-positive rate, and comparability ratio of hospital discharge diagnosis codes for acute myocardial infarction in four US communities, 1987-2000. Am J Epidemiol 2004; 160: 1137-1146.
16. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med 1999; 14: 555-558. (Pubitemid 29441635)
17. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf 2008; 17: 20-26. (Pubitemid 351166614)
18. RayWA, Meador KG. Antipsychotics and sudden death: is thioridazine the only bad actor? Br J Psychiatry 2002; 180: 483-484.
19. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234-241. (Pubitemid 38314873)
20. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-1167. (Pubitemid 33121508)
21. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089-1096. (Pubitemid 39167513)
22. Arbogast PG, Kaltenbach L, Ding H, RayWA. Adjustment for multiple cardiovascular risk factors using a summary risk score. Epidemiology 2008; 19: 30-37.
23. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998; 54: 948-963.
24. Strom B. Pharmacaoepidemiology, (4th edn), John Wiley and Sons: Philadelphia, 2005.
25. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117: 2104-2113. (Pubitemid 351572169)
26. Roumie CL, Mitchel EF, Jr, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39: 2037-2045.
27. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999; 47: 749-754. (Pubitemid 29266647)
28. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303. (Pubitemid 43797117)
29. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998; 54: 948-963.
30. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-1764.
31. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-363. (Pubitemid 18209192)
32. Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care 1976; 14: 166-172.
33. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1-12. (Pubitemid 17094491)
34. Gurwitz JH, Avorn J, Ross-Degnan D, Lipsitz LA. Nonsteroidal antiinflammatory drug-associated azotemia in the very old. Jama 1990; 264: 471-475. (Pubitemid 20223886)
35. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal antiinflammatory drug therapy. Jama 1994; 272: 781-786. (Pubitemid 24275690)
36. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465-1470. (Pubitemid 30327449)
37. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990; 112: 568-576.